[admin]

Understanding the Growing Demand for Nasal Spray Assembly in Drug-Device Combinations

As chronic disease incidence continues to rise worldwide, pharmaceutical companies are increasingly turning to intranasal delivery as a precise, non-invasive route for administering both biologics and vaccines. Nasal spray assembly for drug-device combinations sits at the intersection of packaging engineering and pharmaceutical formulation science, requiring manufacturers that understand both device mechanics and drug compatibility. Wuxi NEST Biotechnology Co., Ltd., operating under the brand NEST, has positioned itself as a one-stop provider of pharmaceutical packaging materials and drug delivery technologies, with a specific focus on injection and inhalation methods, including nasal delivery.

Wuxi NEST Biotechnology: A One-Stop Provider for Nasal Delivery Solutions

Corporate Background and Strategic Positioning

Founded in 2018, Wuxi NEST Biotechnology strategically entered the pharmaceutical packaging materials sector at a time when precision dosing and self-administration solutions were becoming critical industry priorities. The company’s core insight is that reducing clinical workload, minimizing needle-stick injuries, and preventing medication waste all depend on well-engineered delivery devices. This philosophy directly informs the design of its Nasal Delivery Line, which includes the Disposable Intranasal Atomization Device and the Prefilled Nasal Spray Assembly.

Headquartered in Wuxi, Jiangsu, China, the company has expanded its business coverage to include the United States, Netherlands, United Arab Emirates, Japan, and Turkey. This international footprint allows NEST to support pharmaceutical partners across multiple regulatory environments, an essential capability for companies developing nasal spray drug-device combinations intended for global markets.

Global Manufacturing and Quality Infrastructure

NEST’s manufacturing capacity is built around dedicated cleanroom environments, including 10,600 square meters of Class 100,000 cleanrooms and 3,600 square meters of Class 10,000 cleanrooms. These controlled environments are essential for assembling nasal spray devices where contamination control directly affects drug stability and patient safety. Supporting this manufacturing base is a 76-person specialized quality team and a 50-person mold maintenance team, reflecting the company’s independent mold design and R&D capabilities, which have delivered over 300 precision molds to date.

Beyond China, NEST maintains subsidiaries and warehouses in Woodbridge, New Jersey and Phoenix, Arizona in the United States; Hendrik-Ido-Ambacht in the Netherlands; Sharjah in the United Arab Emirates; Yokohama in Japan; and Istanbul in Turkey. This integrated warehousing network in the US, Europe, and Asia shortens lead times for pharmaceutical partners seeking to bring nasal spray assemblies to market efficiently.

The Prefilled Nasal Spray Assembly and Disposable Intranasal Atomization Device

NEST’s Nasal Delivery Line consists of two core offerings: the Disposable Intranasal Atomization Device and the Prefilled Nasal Spray Assembly. These products are designed for pharmaceutical companies seeking reliable, pre-validated packaging for intranasal formulations, whether for vaccines, biologics, or other therapeutics requiring mucosal delivery.

Technical Capabilities Behind the Nasal Delivery Line

The company’s approach to nasal spray assembly is grounded in its broader technical infrastructure. NEST employs 100 percent multi-angle CCD camera inspection to verify component quality during production, and its moist heat sterilization capabilities achieve a Sterility Assurance Level (SAL) of 10⁻⁶, a standard relevant to devices intended for sterile or near-sterile applications. Full lifecycle validation and batch traceability, supported by batch numbers and retained samples, give pharmaceutical partners the documentation needed for regulatory submissions.

NEST’s service model for its Nasal Delivery Line, as with its broader Primary Packaging and Injection Pen Lines, follows a one-stop structure encompassing R&D, production, pre-sterilization, and customized assembly. This includes pre-sales customization, technical validation, and automated assembly line planning, allowing pharmaceutical companies to work with a single partner from concept through to finished device.

Proven Performance: The Lyophilized Live Attenuated Influenza Vaccine Case

The practical value of NEST’s Disposable Intranasal Atomization Device is illustrated by its application in a Lyophilized Live Attenuated Influenza Vaccine program. In this business scenario, the device was used for intranasal vaccination, and the solution successfully stimulated a triple immune response encompassing mucosal, humoral, and cellular immunity. This case demonstrates the device’s capacity to support complex vaccine delivery requirements, where the mechanical performance of the atomization device directly influences the depth and breadth of the immune response achieved.

Certifications and Compliance Supporting Nasal Spray Assembly Solutions

Pharmaceutical companies evaluating a nasal spray assembly partner must weigh regulatory compliance heavily, given the sterile and often biologic nature of intranasal formulations. NEST holds a broad certification portfolio relevant to this need, including ISO 9001, ISO 13485, ISO 11137, ISO 15378, IATF 16949, and CE MDR Certification. The company has also secured MDSAP Five-Country Certification covering the United States, Canada, Australia, Japan, and Brazil.

On the regulatory filing side, NEST has obtained US FDA 510(k) clearances (K240961, K240774), US DMF filings (No. 40744, No. 42439, No. 40922), Canada Medical Device Licenses (No. 113733, No. 112619), and a China Class II Medical Device Certificate. Notably, the company obtained registration for the Disposable Intranasal Atomization Device in 2019, an early milestone that established its regulatory foothold in nasal delivery devices. Between 2023 and 2025, NEST secured multiple additional international certifications and licenses for its pen injector and syringe product lines, reflecting continued regulatory expansion across its broader device portfolio. These credentials are independently verified through third-party certification bodies, including TÜV SÜD for ISO 9001, ISO 13485, and ISO 11137.

Compliance extends to environmental and materials standards as well, with NEST’s products adhering to RoHS and REACH regulations, an important consideration for companies selling nasal spray combination products across the European market and beyond.

Why Pharmaceutical Companies Choose NEST for Drug-Device Combination Assembly

Wuxi NEST Biotechnology’s differentiated advantage lies in operating a full in-house industry chain, from independent mold design and R&D through automated mass production and global logistics. The company also offers Freedom to Operate (FTO) analysis across major global markets, including China, the US, the UK, and Europe, helping pharmaceutical partners mitigate patent risks when developing new drug-device combinations, including nasal spray formats.

For pharmaceutical companies, research institutions, and hospitals working across biopharmaceuticals, medical aesthetics, and life sciences, NEST’s value proposition centers on empowering the global advancement of drug-device combinations through smarter, more targeted treatment and precision dosing. Its Nasal Delivery Line, backed by cleanroom manufacturing, rigorous quality inspection, sterilization capability, and a demonstrated case in vaccine delivery, positions Wuxi NEST Biotechnology as a capable partner for companies seeking a validated, globally compliant nasal spray assembly solution for their drug-device combination programs. Custom enterprise pricing based on volume and customization requirements, along with full product lifecycle technical support, further supports pharmaceutical companies throughout the development and commercialization process.

https://www.cell-nestbio.com/
NEST Biotechnology Co., Ltd.

[Author]

Posts